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Protocol
AbstrACt
Introduction Manual determination of insulin dosing 
largely fails to optimise glucose control in type 1 
diabetes. Automated insulin delivery via closed-loop 
systems has improved glucose control in short-term 
studies. The objective of the present study is to 
determine the effectiveness of 6 months’ closed-loop 
compared with manually determined insulin dosing 
on time-in-target glucose range in adults with type 1 
diabetes.
Methods and analysis This open-label, seven-centre, 
randomised controlled parallel group clinical trial 
will compare home-based hybrid closed-loop versus 
standard diabetes therapy in Australia. Adults aged 
≥25 years with type 1 diabetes using intensive insulin 
therapy (via multiple daily injections or insulin pump, 
total enrolment target n=120) will undertake a run-in 
period including diabetes and carbohydrate-counting 
education, clinical optimisation and baseline data 
collection. Participants will then be randomised 1:1 
either to 26 weeks of MiniMed 670G hybrid closed-
loop system therapy (Medtronic, Northridge, CA, USA) 
or continuation of their current diabetes therapy. The 
hybrid closed-loop system delivers insulin automatically 
to address basal requirements and correct to target 
glucose level, while bolus doses for meals require 
user initiation and carbohydrate estimation. Analysis 
will be intention to treat, with the primary outcome 
time in continuous glucose monitoring (CGM) target 
range (3.9–10.0 mmol/L) during the final 3 weeks of 
intervention. Secondary outcomes include: other CGM 
parameters, HbA1c, severe hypoglycaemia, psychosocial 
well-being, sleep, cognition, electrocardiography, costs, 
quality of life, biomarkers of vascular health and hybrid 
closed-loop system performance. Semistructured 
interviews will assess the expectations and experiences 
of a subgroup of hybrid closed-loop users.
Ethics and dissemination The study has Human 
Research Ethics Committee approval. The study will 
be conducted in accordance with the principles of 
the Declaration of Helsinki and Good Clinical Practice. 
Results will be disseminated at scientific conferences 
and via peer-reviewed publications.
trial registration number ACTRN12617000520336; Pre-
results.
strengths and limitations of this study
 ► Multicentre, randomised controlled parallel group
trial of 26 weeks home-based hybrid closed-loop
versus standard therapy.
 ► Broad outcomes will be assessed in addition to glu-
cose control: psychosocial, sleep, cognition, ECG,
vascular health biomarkers and health economic
measures.
 ► The standard therapy comparator—multiple daily
insulin injections or insulin pump therapy, without
real-time continuous glucose monitoring—reflects
current practice in Australia for most adults with
type 1 diabetes, though this may not reflect standard 
care in other countries.
 ► The study emphasises education and clinical optimi-
sation for all participants prerandomisation, and the
visit schedule is identical for both groups (by design, 
continuous glucose monitoring information is only
available to the closed-loop group).
 ► This study of adults aged  ≥25 years has glucose
end-points aligned with a concurrent study ex-
amining hybrid closed  loop for young people aged
12 to  <25 years, thereby facilitating comparison
of metabolic outcomes between the two
populations.
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IntroduCtIon
Advances in type 1 diabetes insulin regimens and glucose 
monitoring have occurred over recent decades, facilitating 
improved glucose control and resulting in better health 
and quality of life.1–4 The long-term vascular complica-
tions of type 1 diabetes are reduced by intensive insulin 
therapy compared with less intensive therapy.1 2 Conse-
quently, intensive insulin therapy—with subcutaneous 
administration via either multiple daily injections (MDI) 
or insulin pump therapy (IPT)—is a core strategy in 
current type 1 diabetes management.5 Nevertheless, even 
with modern therapies, only 20%–30% of adults with type 
1 diabetes achieve HbA1c targets,
6 7 and long-term vascular
complications and reduced life expectancy continue to 
be a reality for people with type 1 diabetes.8 9 
Insulin requirements can vary unpredictably. They 
are impacted by time of day, meals, exercise, illness and 
antecedent hypoglycaemia. Manual determination of 
insulin dosing by people with type 1 diabetes requires 
continuous vigilance to maintain glucose levels within a 
healthy range. Insulin dosing decisions carry cognitive 
and emotional burden, and may be inconsistent due to 
fatigue, distress, fluctuating glucose levels or coexistent 
fear of hypoglycaemia. Hence, manual determination of 
insulin dosing represents an imperfect strategy to opti-
mise glucose control. Further advances in technology 
are required to improve the match of insulin delivered 
to individuals’ varying insulin requirements, and to mini-
mise the burden of type 1 diabetes.
Closed-loop systems are designed to maintain glucose 
levels at a predetermined target by linking continuous 
glucose monitoring (CGM) information with an insulin 
dosing algorithm for automated subcutaneous insulin 
delivery by a pump.10 These systems are being developed 
to address the need for improving glucose control while 
reducing the burden associated with treatment regimens. 
There is increasing scientific literature of randomised 
controlled studies reporting improved glucose control 
with short-term use of closed-loop systems (up to 3 
months) compared with conventional insulin pumps.11–15 
A recent meta-analysis of outpatient randomised 
controlled trials with intervention periods ranging from 
4 days to 12 weeks reported that single-hormone (insulin 
alone) closed-loop systems improve time-in-target 
glucose range and reduce time spent in hypoglycaemia 
compared with conventional IPT (with/without CGM).16 
Overall, time-in-target glucose range had a mean (95% 
CI) absolute increase of 11.1% (6.9, 15.2), and the time
spent in hypoglycaemia had an absolute reduction of
1.9% (0.4, 3.4). Studies in this meta-analysis used ‘hybrid
closed-loop’ systems with automated insulin delivery to
address basal requirements and correct to target glucose,
and user-initiated bolus insulin to address carbohydrate
consumption. Results from a short-term randomised
crossover study challenging a closed-loop system with
both moderate-intensity and high-intensity exercise indi-
cated that closed-loop glucose control was safe; only a
single episode of mild hypoglycaemia occurred and
marked hyperglycaemic excursions were limited.17 In an 
uncontrolled study, there were no safety concerns when 
14 participants used free-living closed-loop 24/7 for 6 
months.18
For individuals with type 1 diabetes, both hypogly-
caemia and hyperglycaemia can affect physical and 
emotional well-being, quality of life and activities of daily 
living such as driving.4 19–21 Moreover, type 1 diabetes 
places significant burden on caregivers, families, work-
places and health services.22–24 Closed-loop technology 
has shown promise to address the limitations of current 
therapy in relation to these burdens.25 Qualitative and 
small-scale quantitative substudies in closed-loop trials 
have shown user acceptability and treatment satisfaction 
are high with closed-loop systems in home settings, partic-
ularly for overnight use when there is minimal manual 
interaction for meals and activity.26–28 Although intrusive 
device alerts, device size and technical difficulties can 
negatively affect the overall experience, users typically 
report benefits outweighing annoyances, which they 
anticipate will be overcome with future iterations of the 
technology.27–29 However, the only published randomised 
closed-loop trial involving adults to have included estab-
lished, validated psychological measures reported no 
between-group differences in treatment satisfaction or 
fear of hypoglycaemia.30
HbA1c, a measurement of average glycaemia during the 
preceding 10–12 weeks, predicts the risk of developing 
long-term complications and is valuable for assessing 
glycaemic trends in populations over time.1 2 31 However, 
HbA1c cannot provide information about glucose vari-
ability or time-in-target glucose range, and is even consid-
ered an unreliable indicator of an individual’s mean 
glucose.32 A recent large longitudinal registry study 
reported lower cardiovascular and all-cause mortality in 
individuals using IPT compared with MDI, even without 
between-group differences in HbA1c.
33 The mortality
difference observed may have been attributable to factors 
such as time-in-target glucose range or glucose variability 
(not reflected in HbA1c). Consequently, HbA1c may be of 
limited value in comparison with CGM when assessing 
an individual’s glucose levels in response to automated 
closed-loop insulin delivery.
With short-term randomised controlled studies of 
closed-loop systems (conducted in camp/hotel and 
home settings) demonstrating improvements in glucose 
control,16 it remains to be determined whether these 
findings are sustained in the longer term in the home 
setting and whether diabetes-related vascular compli-
cations may be influenced. Longer term randomised 
controlled home-based studies—with closed loop imple-
mented day and night—are required. In addition, the 
impact of closed-loop insulin delivery on patient-reported 
outcomes such as fear of hypoglycaemia, treatment satis-
faction, sleep quality and cognition remains a significant 
gap in the evidence base.34 Finally, the benefits associated 
with this new technology need to be balanced against its 
cost.
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In Australia, the government presently subsidises the 
purchase of insulin, injection needles, blood glucose 
monitoring strips and insulin pump delivery consum-
ables for people with type 1 diabetes.35 Insulin pumps 
are not government subsidised, but are available via 
either direct purchase or in conjunction with a private 
health insurance fund. CGM is government subsidised 
only for eligible individuals under 21 years of age.36 As a 
result, only a small fraction of adults with type 1 diabetes 
use CGM on a regular basis. Hence, standard diabetes 
therapy for adults in Australia currently involves subcu-
taneous intensive insulin therapy delivered via either 
MDI or pump, together with finger-prick blood glucose 
monitoring.
We hypothesise that hybrid closed-loop insulin delivery 
compared with manually determined insulin dosing 
(without CGM) will improve time-in-target glucose 
range for adults with type 1 diabetes. The overall aim of 
the study is to evaluate the effect of 6 months of hybrid 
closed-loop insulin delivery on glucose control, psycho-
social well-being, sleep quality, cognition and markers 
of vascular disease risk compared with standard diabetes 
therapy for adults with type 1 diabetes.
MEthods And AnAlysIs
overview
This open-label, randomised controlled parallel group 
clinical trial will compare 26 weeks of hybrid closed-loop 
therapy versus ‘standard therapy’ for 120 adults (aged ≥25 
years) with type 1 diabetes (protocol version 2.0, dated 29 
March 2017). The standard therapy comparator consists 
of insulin delivered via either MDI or IPT, without real-
time continuous glucose monitoring (RT-CGM), and 
was chosen to reflect current self-management of type 1 
diabetes among adults in Australia.
The study is being conducted at seven university hospi-
tals across Australia. The University of Melbourne is the 
coordinating academic institution, with St Vincent’s 
Hospital Melbourne (Melbourne) the study sponsor and 
lead clinical site. Other clinical sites are: Flinders Medical 
Centre (Adelaide), Royal Hobart Hospital (Hobart), 
Royal Melbourne Hospital (Melbourne), Sir Charles 
Gairdner Hospital (Perth), The Alfred and Baker Heart 
and Diabetes Institute (Melbourne) and Westmead 
Hospital (Sydney). Other academic institutions involved 
are Sydney University and Deakin University. In parallel, 
a similar study of younger people (aged 12 to <25 years) 
with type 1 diabetes is being undertaken in Australia; 
the hybrid closed-loop system and primary outcome are 
aligned for the two studies.
study outcomes
The study outcomes are listed in box 1.
The primary study outcome is the proportion of sensor 
glucose time-in-target range (3.9–10.0 mmol/L) with 
hybrid closed-loop versus standard therapy, measured 
by masked CGM 23–26 weeks postrandomisation. This 
box 1 study outcomes
Primary outcome
The proportion of time sensor glucose is in target range (3.9–
10.0 mmol/L) with hybrid closed-loop versus standard therapy (multiple 
daily injections (MDI) or insulin pump therapy (IPT) without real-time 
continuous glucose monitoring (RT-CGM)), measured by masked CGM 
at 23–26 weeks postrandomisation.
secondary outcomes
Hybrid closed-loop therapy versus standard therapy (overall and 
for each of baseline MDI and IPT separately) for the measures listed 
below.
1. Glucose control:
a. Masked CGM metrics for 24 hours/day, day (06:00–00:00) and
night (00:00–06:00) (measured at mid-study, end of study and
mid-study plus end of study combined):
i. Proportion of time spent 3.9–10.0 mmol/L (excluding the
primary outcome).
ii. Proportion of time spent <2.8 mmol/L.
iii. Proportion of time spent <3.3 mmol/L.
iv. Proportion of time spent <3.9 mmol/L.
v. Proportion of time spent 3.9–7.8 mmol/L.
vi. Proportion of time spent >10.0 mmol/L.
vii. Proportion of time spent >13.9 mmol/L.
viii. Proportion of time spent >16.7 mmol/L.
ix. SD and coefficient of variation.
x. Mean glucose.
b. Fasting capillary blood glucose.
c. HbA
1c.
d. 1,5-anhydroglucitol.
e. Symptomatic hypoglycaemia (with blood glucose <3.5 mmol/L)
requiring carbohydrate rescue (n).
2. Clinical:
a. Change in total daily dose of insulin, and basal/bolus proportions.
b. Change in insulin-to-carbohydrate ratio.
c. Change in body weight.
3. Psychosocial, sleep and cognitive functioning:
a. Treatment satisfaction: the Diabetes Treatment Satisfaction
Questionnaire (DTSQ) status and change versions.
b. Satisfaction with technology: Diabetes Management Experiences 
Questionnaire (DME-Q).
c. Fear of hypoglycaemia: Hypoglycaemia Fear Survey short form
(HFS-SF).
d. Fear of hyperglycaemia: Hyperglycaemia Avoidance Scale (HAS).
e. Hypoglycaemia Awareness: Gold Score.
f. Diabetes distress: Problem Areas in Diabetes (PAID).
g. Diabetes-specific quality of life: DAWN Impact of Diabetes profile 
(DIDP).
h. Diabetes-specific positive well-being: Well-being Questionnaire
(W-BQ28) Positive Diabetes Well-being Subscale.
i. Cognitive function: Prospective and Retrospective Memory
Questionnaire (PRMQ) and Psychomotor Vigilance Task
(PVT-192).
j. Driving: proportion of time-in-target glucose range while driving
(Melbourne sites only).
k. Sleep quality: Actigraph data, Pittsburgh Sleep Quality Index,
Karolinska Sleepiness Scale.
4. Electrocardiograph profile (via Holter monitor):
a. Corrected QT interval (QT
c).
b. Heart rate.
c. Cardiac arrhythmias.
Continued
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primary end-point was selected to provide the best indi-
cation of individual participants’ glucose control. The 
3.9–10.0 mmol/L glucose range is aligned with outcome 
metrics proposed by the JDRF Artificial Pancreas Project 
Consortium, is consistent with available data relating 
glucose control and complication prevention, and 
represents a realistic glucose target.32 37 The secondary 
outcomes are listed in box 1, sections 1–9.
CGM study outcome data will be collected by identical 
methods for participants in both groups. Hence, partici-
pants assigned hybrid closed-loop therapy will wear two 
identical glucose sensors for 2 weeks mid-study and 3 
weeks at end of study—one sensor providing RT-CGM 
information to the user and directly linking to the hybrid 
closed-loop system, and a second sensor collecting masked 
CGM study outcome data. The closed-loop system perfor-
mance parameters chosen as study outcome measures are 
based on an international consensus report for outcome 
measures in closed-loop trials.37
For closed-loop technology to achieve long-term clin-
ical benefits, then in addition to positively impacting 
biomedical outcomes, user acceptance, uptake and adap-
tations are required.28 38 Therefore, this study will assess 
aspects of psychosocial well-being via both subjective 
(questionnaires, interviews) and objective (actigraph, 
psychomotor task) methods. This holistic approach will 
progress understanding of the human factors involved, 
thereby enabling adaption of the technology in line with 
the person’s expectations and experiences.39 The study 
will also assess whether CGM has an impact on utilisation 
of health services and medications.
Eligibility
Inclusion and exclusion criteria for participation are 
listed in box 2.
The minimum inclusion age of 25 years was chosen to 
reflect a general adult population with type 1 diabetes 
while avoiding potential confounders associated with 
adolescence and emerging adulthood. This decision was 
box 1 Continued
5. Human–technology interaction (participants using hybrid closed-
loop system):
a. Participant perceptions of the hybrid closed-loop system as-
sessed via short message service (SMS) data collection.
b. Participant expectations and experiences with the hybrid closed-
loop system assessed via longitudinal semistructured interviews
(Melbourne sites only).
6. Health economic:
a. Quality-adjusted life years calculated from the EQ-5D-5L.
b. Hypoglycaemic events and HbA
1c.
c. Participant and family reporting on work interruption.
d. Reported time spent on training, education and support, by the
type of health professional resource used.
e. Diabetes management consumables (glucose strips, ketone
strips, batteries, sensors, site dressings, lancets, needles, insulin).
f. Resource utilisation tracked via linked administrative data from
the Australian Medicare Benefits Schedule and Pharmaceutical
Benefits Scheme.
7. Biochemical markers of vascular disease risk:
a. Cell adhesion molecules.
b. Oxidised low-density lipoprotein.
c. Myeloperoxidase.
d. MicroRNA signatures for arterial, renal and retinal complications.
e. Telomerase.
f. DNA methylation/acetylation.
g. Isoprostanes (blood and urine) and proteomics.
h. Clotting profile.
8. Hybrid closed-loop system performance parameters:
a. Proportion of time closed-loop active.
b. Unplanned exits from closed loop (n).
c. Sensor performance versus blood glucose metre as measured by 
mean absolute relative difference (MARD) and sensor failures (n).
d. Reported insulin delivery line failures (n).
e. Participant calls to the technical help line (n).
9. Safety:
a. Hospitalisations for diabetic ketoacidosis (n).
b. Severe hypoglycaemia, defined as hypoglycaemia requiring the
assistance of another person to actively administer carbohydrate, 
glucagon, or take other corrective actions (n).
box 2 Eligibility
Inclusion criteria
 ► Type 1 diabetes (as defined by the American Diabetes Association)49
for at least 1 year.
 ► Insulin regimen consisting of either:
 – Multiple daily injections (MDI) with ≥4 injections per day (includ-
ing ≥3 rapid-acting insulin injections and ≥1 long-acting insulin
injection). 
 – Insulin pump therapy (IPT) established for ≥3 months.
 ► Ages 25–70 years inclusive.
 ► HbA1c ≤10.5% (≤91 mmol/mol).
 ► Living in an area with internet and cellular phone coverage.
 ► English speaking proficiency.
Exclusion criteria
 ► Chronic kidney disease (estimated glomerular filtration rate
(eGFR) <45 mL/min/1.73 m2).
 ► Current use of real-time continuous glucose monitoring (RT-CGM)
(defined as use >25% of the time during the past 3 months).
 ► Use of any non-insulin glucose-lowering agent within the past
3 months.
 ► Oral or injected steroid use within the past 3 months.
 ► Pregnancy, or pregnancy planned within study period.
 ► Untreated coeliac disease or other malabsorption.
 ► Uncontrolled thyroid disease.
 ► Clinically significant gastroparesis.
 ► Uncontrolled hypertension (blood pressure: diastolic >100 or systol-
ic >160 mm Hg).
 ► History of myocardial infarction, severe uncontrolled heart failure,
unstable angina, transient ischaemic attack, stroke, or thromboem-
bolic disease in the past 3 months.
 ► Poor visual acuity precluding use of the study technology.
 ► Inability or unwillingness to meet protocol requirements.
 ► Any severe or unstable medical or psychological condition which, in
the opinion of the investigator, would compromise the ability to meet 
protocol requirements.
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informed by results of previous type 1 diabetes CGM and 
closed-loop studies, where individuals aged <25 years 
differed from those aged ≥25 years.14 40
Use of RT-CGM >25% of the time precludes inclusion. 
This decision was informed by study findings that adults 
aged ≥25 years with type 1 diabetes using RT-CGM with 
warning alarms had improved glucose control without 
increase in biochemical hypoglycaemia only when 
RT-CGM was worn ≥5–6 days/week.40–42 When CGM is 
used less often, or without warning alarms, evidence 
suggests no glucose control benefit.
study diabetes management devices
Hybrid closed-loop system
The study hybrid closed loop is the MiniMed 670G system, 
comprising a glucose sensor and transmitter coupled 
with an insulin pump containing a closed-loop algorithm 
(Medtronic, Northridge, CA, USA), and rapid-acting 
analogue insulin (either insulin aspart or insulin lispro) 
delivered subcutaneously. CGM data are transmitted to 
the pump every 5 min and the algorithm calculates the 
basal insulin dose (delivered at 5 min intervals) required 
to maintain the target glucose level. The algorithm uses 
a modified proportional integrative derivative model with 
insulin feedback based on an insulin delivery algorithm 
originally developed by Steil et al.43 The algorithm also 
incorporates a supervisory model predictive component 
aiming to avoid insulin overdelivery.44 For meals, the user 
estimates the amount of carbohydrate to be consumed 
(entering this into the pump) and checks their capillary 
blood glucose level. Using this information, an insulin 
bolus is calculated and delivered according to the indi-
vidualised insulin-to-carbohydrate ratio and an insulin 
sensitivity factor determined by the algorithm (should a 
correction bolus be required).
The MiniMed 670G system has been deemed safe and 
effective for glucose control in a 3-month uncontrolled 
study45 46 and an exercise study.17 The system was approved 
for use by the US Food and Drug Administration in 2016.
Masked CGM
CGM data masked to both the participants and research 
team will be collected for study outcome measurements at 
three time points: baseline prerandomisation (3 weeks), 
mid-study (2 weeks) and end of study (3 weeks). For partic-
ipants randomised to hybrid closed loop, this masked 
CGM data collection will be in addition to the system’s 
RT-CGM. The study uses Guardian Sensor 3 glucose 
sensors (Medtronic, Northridge, CA, USA). This sensor 
configuration has reported performance parameters 
of mean absolute relative difference±SD of 9.6%±9.0% 
and mean functional sensor life of 146±39 hours when 
used with a Medtronic MiniMed 640G insulin pump.47 
By using a separate device to collect CGM study outcome 
data, the device under investigation is not also being used 
to evaluate its own performance.
For masked CGM data collection, the glucose sensor 
will be inserted and the sensor recorder will be connected 
by the study team. During masked CGM, participants will 
be required to test capillary blood glucose levels at least 
four times per day with a CONTOUR NEXT LINK metre 
(details below). Masked CGM data are collected retro-
spectively by uploading the recorder and the metre.
Blood glucose monitoring
All participants will be provided with a CONTOUR 
NEXT LINK 2.4 blood glucose metre (Ascensia, Parsip-
pany, NJ, USA) which is able to transmit data directly 
to the MiniMed 670G insulin pump. Prerandomisation, 
and for participants randomised to standard therapy, the 
CONTOUR NEXT LINK 2.4 will be used in addition to 
their regular glucose metre during masked CGM. Use 
of the same glucose metre within the hybrid closed-loop 
system and for masked CGM calibration will standardise 
data collection.
Participants using MDI at enrolment will also be provided 
with an ACCU-CHEK Aviva Expert blood glucose metre 
(Roche Diagnostics, Mannheim, Germany), selected for 
its in-built ‘bolus calculator’. The bolus calculator uses 
the measured blood glucose level, calculated rapid-acting 
‘insulin on board’, and the programmed insulin sensi-
tivity factor and insulin-to-carbohydrate ratio to deter-
mine the recommended insulin bolus doses. The use of a 
metre with bolus calculator by those in the control group 
who continue with MDI will reflect the bolus calculators 
used by participants randomised to hybrid closed-loop 
therapy and by those using IPT randomised to standard 
diabetes therapy.
Diabetes management software
CareLink, an internet-based platform from Medtronic, 
will be used for uploading insulin pump, glucose sensor 
and glucose metre data. The hybrid closed-loop system 
data are uploaded to a computer via the system’s glucose 
metre USB connection; insulin pump, sensor and metre 
data are then accessible to study investigators.
study design
This is a prospective, open-label, parallel design 
randomised controlled study involving adults with type 
1 diabetes (overall target n=120, with ≥40% using MDI 
and ≥40% using IPT). Study procedures will be under-
taken by medical doctors with subspecialty training in 
endocrinology, diabetes nurse educators, dietitians and 
research nurses. Throughout the study, the time taken 
for participant education, training, clinical care and 
technical support will be recorded; the health profes-
sional time will be used in health economic analyses to 
determine implications for closed loop becoming a main-
stream therapy. Adherence to study protocols will be 
assessed at each study visit; verbal and written reminders 
of study instructions will be provided to improve protocol 
adherence. Participants will continue their usual diabetes 
clinical care with their treating clinicians during study 
participation. Participants will be randomised 1:1 either 
to hybrid closed-loop therapy or to continue using their 
6 McAuley SA, et al. BMJ Open 2018;8:e020274. doi:10.1136/bmjopen-2017-020274
Open access 
current standard diabetes therapy (either MDI or IPT) for 
26 weeks (figure 1). Use of RT-CGM will not be permitted 
during run-in or by participants randomised to standard 
diabetes therapy (though CGM without live alerts, eg, 
Abbott FreeStyle Libre, is permissible).
Patient involvement
Investigator discussions with patients throughout provi-
sion of clinical care and during previous research studies 
were taken into consideration when designing this study 
protocol. The burden of the study intervention will be 
assessed via short message service data collection and 
during semistructured interviews (see box 1, sections 5a 
and 5b).
sample size
The power calculation is for a parallel study design 
with two groups of equal size. It is based on SDs of the 
percentage time-in-target glucose range at 6 months 
(adjusted for baseline) observed for the subset of partic-
ipants in two randomised clinical trials from the JDRF 
Study Group who had similar characteristics to partici-
pants being recruited here (Professor Roy Beck, personal 
communication). The SD (95% CI) for pump users was 
9% (8%, 12%) and for MDI users was 10% (7%, 19%).
From an initial overall sample size of n=120, with a 
dropout rate of 10%, a common SD of 9% and a type I 
error rate of 5%, the power to detect a minimum absolute 
difference of 5% time-in-target glucose range would be 
80%. A more conservative scenario with a dropout rate 
of 20%, and unequal SDs of 12% and 19% for pump and 
MDI users, respectively, increases the minimum detect-
able absolute difference to 9% with power of 80%.
study schedule
The study will consist of 16 visits including the run-in 
and intervention periods. Key activities undertaken 
during each visit are shown in table 1. Participants will be 
provided with 24 hours’ telephone contacts for support 
if required. Health professionals will log all time taken 
training and communicating with the study participants.
Run-in period
After enrolment, there will be a run-in period lasting at 
least 5 weeks. Participants will undergo initial medical, 
psychosocial and cognitive assessments. Their diabe-
tes-related knowledge and carbohydrate-counting profi-
ciency will be assessed and their insulin dosing will be 
optimised. Participants will be provided with detailed 
training and support to use the study glucose metres 
and masked CGM devices. Education will be provided 
by diabetes nurse educators and dietitians to opti-
mise participants’ diabetes self-management including 
carbohydrate counting. The optimisation of carbohy-
drate counting is central to baseline optimisation for all 
participants in the study—this aims to achieve the best 
possible match of bolus insulin doses to the individuals’ 
requirements for the carbohydrate consumed for both 
groups, thereby testing the closed-loop aspect of the 
hybrid closed-loop system’s insulin delivery in compar-
ison with standard therapy.
After provision of education, data will be collected for 
3 weeks of baseline masked CGM, actigraphy (sleep data) 
and from the self-reported diabetes logbook. Driving 
log data (to associate with the CGM data) will also be 
collected during these 3 weeks for participants at the 
three clinical sites in Melbourne. At the end of the run-in 
period, the CGM data will be uploaded and checked to 
ensure data are available for at least 70% of the time.40 
If the minimum required CGM data are not available, an 
additional week of CGM will be undertaken to fulfil the 
protocol requirements. At the end of the run-in, baseline 
blood and urine samples will be collected for measure-
ment of HbA1c and biochemical markers of vascular 
disease risk.
Figure 1 Study protocol overview.
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Randomisation
Eligible participants will be randomised after completing 
the run-in. Group allocation will be a 1:1 ratio using mini-
misation with three variables, all of which are expected 
to be highly prognostic of the primary outcome. These 
minimisation variables are: (1) the proportion of time-
in-target glucose range at baseline (dichotomised to 
≤50% and >50%); (2) study centre (seven clinical sites);
and (3) insulin delivery modality (MDI or IPT). Rando-
misation will be performed by an independent group of
statisticians using central randomisation software, and
will be implemented into an electronic participant record
system.
The nature of the study groups does not allow blinding 
of participants or investigators.
Intervention period
After randomisation, there will be a 26-week intervention 
period.
Participants randomised to standard therapy will 
continue using their current insulin delivery modality 
(MDI or IPT, with bolus calculator in the glucose metre 
or pump, respectively) and will be instructed to refrain 
from using RT-CGM during the study.
Participants randomised to hybrid closed-loop therapy 
will receive general insulin pump and CGM education 
and training, plus instruction regarding usage of the 
study hybrid closed-loop system. This education and 
training period may take up to 4 weeks (likely longer 
for those using MDI than IPT at baseline). The hybrid 
closed-loop system will be programmed with participants’ 
usual insulin-to-carbohydrate ratios and insulin sensitivity 
factors, as well as their usual basal rates (or the basal rates 
determined by their clinicians for those participants tran-
sitioning from MDI). Participants will be provided with a 
24 hours’ technical help telephone contact for the hybrid 
closed-loop system.
Participants at the three clinical sites in Melbourne 
who are randomised to hybrid closed-loop therapy will 
undergo four semistructured interviews to assess their 
expectations of, and experiences with, the technology. 
These interviews will be conducted at randomisation, 
then at 11, 26 and 39 weeks postrandomisation.
Participants will have mid-study data collected between 
11 and 13 weeks postrandomisation. Two weeks of 
masked CGM data, cognitive assessments and actigraphy 
will be collected, plus driving data for participants at 
the Melbourne sites. Clinical review with assessment of 
diabetes management and carbohydrate counting, and 
adjustment of therapy and further education as required, 
will be undertaken 13 weeks postrandomisation. At this 
visit, psychosocial questionnaires will be completed and 
venous samples for HbA1c will be collected.
Participants will have end-of-study data collected 
between 23 and 26 weeks postrandomisation. Three 
weeks of masked CGM data, cognitive assessments 
and actigraphy will be collected, plus driving data for 
Table 1 Study visits
Study visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Weeks from randomisation −3 −2 −1 0 1 ~7 11 12 13 23 24 25 26 26 39
Clinical assessment X X X X
Time with health professional X X X X X X X X X X X X X X X
HbA1c X X X X
β-hCG, C-peptide X
CHO counting education X X
Insulin pump training X
Insulin dose review X X X X
Logbook provision X
Logbook data collection X X X X X X X X X X X X X
Masked CGM insertion X X X X X X X X
Glucose metre upload X X X X X X X X X X X X X
Psychosocial, sleep, cognitive 
functioning surveys
X X X
Cognitive performance device provision X X X
Actigraphy and sleep diary provision X X X X X X X X
Semistructured interviews X X X X
Driving device and diary provision X X X X X X X X
Holter monitor provision X X X
Vascular disease risk markers X X
CGM, continuous glucose monitoring; CHO, carbohydrate. 
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participants at the Melbourne sites. At the end of the 
3-week period, the CGM data will be uploaded and
checked for available data at least 70% of the time. If
70% of CGM data are not available, an additional week
of CGM data will be collected. At the end-of-study visit
(26 weeks postrandomisation), psychosocial question-
naires will be completed, and venous and urine samples
will be collected for HbA1c and biochemical markers of
vascular disease risk. Participants in the hybrid closed-
loop group will change back to using their usual insulin
delivery modality (MDI or IPT). Doctor visit data from
the Medicare Benefits Schedule and insulin prescription
data from the Pharmaceutical Benefits Scheme will be
accessed for study participants.
statistical methods
The primary analysis will assess differences in the 
proportion of time-in-target glucose sensor range (3.9–
10.0 mmol/L) with hybrid closed-loop versus standard 
therapy, measured by masked CGM at 23–26 weeks 
postrandomisation on an intention-to-treat basis using 
analysis of covariance (ANCOVA) with adjustment 
for baseline time-in-target range. A p value threshold 
of <0.05 will be used to determine statistical significance.
Model fit will be evaluated by exploration of residuals. 
If the model is of poor fit, the outcome variable will be 
transformed and the model refitted and evaluated. If 
unsuccessful, non-parametric analysis will be performed.
Analysis of continuous secondary outcomes will also 
use ANCOVA with adjustment for baseline time-in-target 
range, whereas Poisson or negative binomial regression 
will be used for count outcomes and logistic regression 
will be used for binary outcomes. Subgroup analysis by 
baseline insulin delivery modality will be performed by 
inclusion of an interaction term in the regression model-
ling or by a stratified analysis when non-parametric 
methods are used.
No adjustment for multiplicity is planned. All results for 
primary and secondary outcomes will be reported.48 No 
interim analysis is planned.
health economic evaluation
An economic evaluation will determine the incremental 
cost of home-based hybrid closed-loop versus standard 
diabetes therapy in Australia. This analysis will quantify 
costs directly associated with hybrid closed-loop and stan-
dard diabetes therapy plus other impacts on the health 
system (box 1). Outcomes will be assessed in quality-ad-
justed life years for changes in health-related quality of 
life, and for the likely long-term impact of changes in 
glucose control on long-term outcomes using a type 1 
diabetes simulation model.
safety assessments
Safety parameters to be assessed include severe hypo-
glycaemia, ketoacidosis and unplanned hospitalisations 
directly related to the study (box 1).
Effectiveness assessments
Effectiveness parameters to be assessed include glucose 
control, clinical measures, psychosocial and cognitive 
functioning, human–technology interaction, health 
economic measures and biochemical markers of vascular 
disease risk (box 1).
Closed-loop system performance parameters
Closed-loop system performance parameters to be 
assessed relate to the system overall, to individual system 
components and to system usability (box 1).
trial oversight
The study will be conducted in accordance with the prin-
ciples of the Declaration of Helsinki and guidelines for 
Good Clinical Practice (GCP).
The day-to-day study management will be the respon-
sibility of the investigators at each clinical site. The prin-
cipal investigator and study project manager will maintain 
regular correspondence with all investigators and study 
coordinators. The principal investigator, with the sites’ 
lead investigators, will assume responsibility for the prog-
ress of the study in accordance with agreed timelines 
and milestones with the study funders. A combined data 
safety and monitoring board (DSMB) will be established 
for this study and the aligned study, independent from 
the study investigators, comprising adult and paediatric 
physicians experienced in statistics and clinical trials. The 
study project manager will liaise with the study teams in 
all centres to establish procedures and ensure that the 
study is carried out according to the protocol and to stan-
dards of GCP, with robust systems for reporting adverse 
events. The study project manager will be responsible for 
the central preparations of data for presentation to the 
DSMB.
EthICs And dIssEMInAtIon
The study has received ethics approval from the lead site 
Human Research Ethics Committee. Other clinical sites 
provide oversight through local governance committees. 
Any substantial amendments to the study protocol will be 
reported to the lead site ethics committee for approval 
prior to implementation, and updated on the trial registry, 
with the study investigators being advised in writing.
All potential participants will be provided with written 
and verbal information regarding the study, the proce-
dures involved and all potential risks related to partici-
pating. A study investigator will obtain written informed 
consent from each participant prior to commencing study 
procedures. All personal information about potential and 
enrolled participants will be deidentified to protect confi-
dentiality before, during and after the trial. Standard 
operating procedures for reporting all adverse events, 
device-related adverse events and severe adverse events 
will be in place. The Human Research Ethics Committees 
and the Therapeutic Goods Administration of Australia 
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will be informed of any serious adverse events and any 
unexpected device-related adverse events.
Screening and recruitment commenced in May 2017. 
It is anticipated that the study visits will be completed 
by May 2019. The results of the study will be dissemi-
nated at national and international conferences and by 
peer-reviewed publications. Participants will be provided 
with a summary of the study results by their site’s lead 
investigator.
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